Vercise Genus DBS system received FDA approval 


Boston Scientific has announced that it has received US Food and Drug Administration (FDA) approval for its fourth-generation Vercise Genus deep brain stimulation (DBS) system. 

According to a company press release, the portfolio, approved for conditional use in a magnetic resonance imaging (MRI) environment, consists of a family of Bluetooth-enabled, rechargeable and non-rechargeable, implantable pulse generators (IPGs) that power Cartesia directional leads, designed to provide optimal symptom relief.  

“We have used the Vercise Gevia system with the Cartesia directional leads to provide our patients with a small device, a battery life of at least 15 years and optimal symptom control by delivering the right dose of stimulation precisely where it is needed,” said Jill Ostrem, medical director and division chief, University of California, San Francisco Movement Disorders and Neuromodulation Center, San Francisco, USA. “Now, the latest generation Genus portfoliowith an MR-compatible non-rechargeable IPG as wellprovides greater access to patients who might not be candidates for a rechargeable system.” 


Please enter your comment!
Please enter your name here